Acrivon Therapeutics, Inc.

Develops precision cancer therapies by matching patients to drugs using its proteomics platform.

ACRV | NDAQ

Overview

Corporate Details

ISIN(s):: US0048901096
LEI:
Country:: United States of America
Address:: 480 ARSENAL WAY, SUITE 100, 2472 WATERTOWN
Website:: https://acrivon.com/
Sector:: Mining and quarrying
Industry:: Mining of non-ferrous metal ores

Description

Acrivon Therapeutics, Inc. is a clinical-stage biopharmaceutical company specializing in precision oncology. The company leverages its proprietary Acrivon Predictive Precision Proteomics (AP3) platform to develop targeted cancer therapies. The AP3 platform utilizes phosphoproteomics to analyze the biologic drivers of a patient's cancer, enabling the creation of predictive 'OncoSignature' tests. This method is designed to match drug candidates with patients whose tumors are most likely to respond, aiming to improve therapeutic outcomes beyond what is achievable with genomics. Acrivon's pipeline is led by ACR-368, a selective kinase inhibitor in Phase 2 clinical trials for various solid tumors. The company also advances its internally developed programs and seeks strategic partnerships to apply its AP3 platform to co-develop predictive tests for external drug candidates.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Acrivon Therapeutics, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Acrivon Therapeutics, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for Acrivon Therapeutics, Inc. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
IQVIA HOLDINGS INC. Global provider of analytics, tech, and clinical research for life sciences and healthcare.	United States of America	IQV
Isofol Medical Developing a drug to enhance chemotherapy efficacy for solid tumors like colorectal cancer.	Sweden	ISOFOL
ITOXI Corp. B2B platform for Ukraine-Korea trade, investment, and post-war reconstruction.	South Korea	052770
IVISIONWORKS CO.,LTD. Accelerates social impact startups & develops digital therapeutics for cognitive rehabilitation.	South Korea	469750
Jardine Matheson Hldgs Ltd A diversified, Asia-focused conglomerate with businesses in property, retail, auto, and more.	Bermuda	JARD
JSC National Atomic Co. Kazatomprom The world's largest uranium producer, managing the front-end of the global nuclear fuel cycle.	Kazakhstan	KZAP
KAINOS MEDICINE, INC. Develops small molecule drugs for neurodegenerative diseases, cancers, and infectious diseases.	South Korea	284620
Kanamoto Co., Ltd. Global provider of rental construction equipment, also selling used machinery and steel products.	Japan	9678
Keihan Holdings Co.,Ltd. A conglomerate integrating transport, real estate, and retail for regional development.	Japan	9045
Kezar Life Sciences, Inc. Developing novel small molecule therapies for immune-mediated diseases and oncology.	United States of America	KZR